ICBMT 2024. ICBMT 2024. THE 8th INTERNATIONAL CONGRESS OF BMT 2024. THE 29th ANNUAL CONGRESS OF KSBMT.

Moving Forward into the New Era of HSCT and Cellular Therapy

SEPTEMBER 26(Thu) - 28(Sat), 2024. BEXCO, BUSAN, KOREA
HOME

Scientific Program

SELECT AND VIEW SESSIONS OF YOUR CHOICE
Search

Oral Presentation 1

 Room A
(2F)
Date & Time Sep. 26 (Thu), 09:00-10:00
Chair(s) Min Kyoung Kim (Yeungnam University College of Medicine)
Ho Sup Lee (Kosin University College of Medicine)
Speaker(s) 09:00-09:10 Clinical Implication and Long-term Survival Outcome of Second Allogeneic HCT in Adult Patients with Relapsed Acute Lymphoblastic Leukemia before and after the Era of Novel Immunotherapeutic Agents Daehun Kwag (The Catholic University of Korea)
09:10-09:20 Optimization of Pre-Transplant Conditioning for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia: Interim Phase 2 Results of TBI-Augmented Reduced Toxicity Regimen Incorporating ATG/PTC Jaehyun Ahn (The Catholic University of Korea)
09:20-09:30 Selection of Candidates for Allogenic Hematopoietic Stem Cell Transplantation with T-Lymphoblastic lymphoma by Comparative Study with T-Acute Lymphoblastic Leukemia Tong Yoon Kim (The Catholic University of Korea)
09:30-09:40 Optimization of TBI-Based Myeloablative Conditioning Regimen Incorporating ATG and PTCY in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: Historical Comparison with TBI/CY Jongseo Lee (The Catholic University of Korea)

Oral Presentation 2

 Room B
(2F)
Date & Time Sep. 26 (Thu), 09:00-10:00
Chair(s) Jae Hoon Lee (Gachon University College of Medicine)
Kihyun Kim (Sungkyunkwan University School of Medicine)
Speaker(s) 09:00-09:10 Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma Patients with MRD Positivity after First Transplantation, CARE-MM Study-2401 Sieun Oh (The Catholic University of Korea)
09:10-09:20 CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma Sojeong Kim (Yonsei University College of Medicine)
09:20-09:30 Discoidin Domain Receptor 1 (DDR1) is Associated with Treatment Outcomes in Multiple Myeloma (MM) after Autologous Stem Cell Transplantation Ji-Young Lim (The Catholic University of Korea)
09:30-09:40 Mezigdomide plus Tazemetostat and Dexamethasone for Relapsed or Refractory Multiple Myeloma: Preliminary Results from the CA057-003 Trial Paul Richardson (Dana-Farber Cancer Institute)
09:40-09:50 Evaluating the Efficacy and Safety of Immunotherapeutic T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison Data Analysis Mimicking RCT Sung-Soo Park (The Catholic University of Korea)
09:50-10:00 High B-cell Maturation Antigen Surface Expression on Myeloma Cells is Associated with Poor Survival Outcomes in Patients with Multiple Myeloma Suhyeon Hwang (Yonsei University College of Medicine)

Oral Presentation 3

 Room C
(1F)
Date & Time Sep. 26 (Thu), 09:00-10:00
Chair(s) Inho Kim (Seoul National University College of Medicine)
Seong Hyun Jeong (Ajou University School of Medicine)
Speaker(s) 09:00-09:10 Early Prediction of Hypomethylating Agent Based Therapy Outcome in Elderly Myeloid Disease Patients: A Geriatric Functional Assessment Approach Mihee Kim (Chonnam National University Medical School)
09:10-09:20 Diagnostic NGS Panel-Based Serial Measurable Residual Disease Monitoring as a Prognostic Indicator in Acute Myeloid Leukemia Patients Jae-Sook Ahn (Chonnam National University Medical School)
09:20-09:30 Role of Allogeneic Stem Cell Transplantation in FLT3-ITD Mutated AML Patients Treated with Midostaurin: A Comparative Analysis with Standard Chemotherapy Kyoung Il Min (The Catholic University of Korea)
09:30-09:40 Transplantation Outcomes after Venetoclax-Decitabine Compared to Conventional Chemotherapy as an Induction Therapy: A Propensity Score Matched Cohort Analysis Ka Young Kim (The Catholic University of Korea)
09:40-09:50 Phase I Study to Evaluate Safety of VT-Tri after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Ki-Hyun Park (ViGenCell)
09:50-10:00 Post-Transplant Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Following Gilteritinib Treatment Daehun Kwag (The Catholic University of Korea)

Oral Presentation 4

 Room D
(1F)
Date & Time Sep. 26 (Thu), 09:00-10:00
Chair(s) Hyo Jung Kim (Hallym University College of Medicine)
Yeon Jung Lim (Chungnam National University College of Medicine)
Speaker(s) 09:00-09:10 Risk Factors and Prognosis of Invasive Fungal Disease Following Hematopoietic Stem Cell Transplantation in 1076 Pediatric Patients Jiaming Yu (Shenzhen Children's Hospital)
09:10-09:20 Korean Real-World Data of Defibrotide for Treatment of Adult Patients who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation Jae Ho Yoon (The Catholic University of Korea)

Plenary Session 1

Sep. 26 (Thu), 10:40-12:00 		Room A
(2F)
Chair(s) Ki Woong Sung (Sungkyunkwan University School of Medicine)
  • Waseem Qasim

    10:40-11:20

    Expanding Horizons of CAR T-Cell Therapy through Genome Editing

    Waseem Qasim

    UCL Great Ormond Street Institute of Child Health, UK

  • Sang-Ki Kim

    11:20-12:00

    Innovative Cellular Immunotherapy: Harnessing NK Cells, T Cells, and CAR-based Therapies for Cancer Treatment

    Sang-Ki Kim

    Department of Companion and Laboratory Animal Science, Kongju National University, Korea

Luncheon Symposium 1

Sep. 26 (Thu), 12:10-12:50 		Room A
(2F)
Chair(s) Hyeon-Seok Eom (National Cancer Center)
  • Efstathios Kastritis

    12:10-12:50

    Paving the Future of AL Amyloidosis Treatment with Daratumumab-based Treatment

    Efstathios Kastritis

    National and Kapodistrian University of Athens School of Medicine, Greece

Luncheon Symposium 2

Sep. 26 (Thu), 12:10-12:50 		Room B
(2F)
Chair(s) Sang Kyun Sohn (Kyungpook National University School of Medicine)
  • Dennis Kim

    12:10-12:50

    New Chapter of cGvHD Therapeutics: Belumosudil

    Dennis Kim

    Princess Margaret Cancer Centre, Canada

Luncheon Symposium 3

Sep. 26 (Thu), 12:10-12:50 		Room C
(1F)
Chair(s) Sung-Hyun Kim (Dong-A University College of Medicine)
  • Olaf Penack

    12:10-12:50

    Invisible Invaders: All Things to Know about Fungal Infection in Hematology

    Olaf Penack

    Charité - Universitätsmedizin Berlin, Germany

Luncheon Symposium 4

Sep. 26 (Thu), 12:10-12:50 		Room D-1
(1F)
Chair(s) Jong Wook Lee (Hanyang University Medical Center)
  • Jun Ho Jang

    12:10-12:50

    From Second-Line to First-line: The Evolving Role of Romiplostim in Severe Aplastic Anemia Management

    Jun Ho Jang

    Sungkyunkwan University School of Medicine, Korea

Luncheon Symposium 5

Sep. 26 (Thu), 12:10-12:50 		Room D-2
(1F)
Chair(s) Hee-Je Kim (The Catholic University of Korea)
  • Dong-Yeop Shin

    12:10-12:50

    How I Manage of Unfit AML Patients with Venetoclax for Long-term Survival

    Dong-Yeop Shin

    Seoul National University College of Medicine, Korea

Plenary Session 2

Sep. 26 (Thu), 13:00-14:20 		Room A
(2F)
Chair(s) Jong Wook Lee (Hanyang University Medical Center)
  • Kate Markey

    13:00-13:40

    Exploring the Influence of the Microbiome on Hematopoiesis and Immune Reconstitution

    Kate Markey

    Fred Hutchinson Cancer Center, USA

  • Donal McLornan

    13:40-14:20

    Unraveling the Significance of Germline Predisposition Mutations in MDS prior to Transplantation

    Donal McLornan

    University College London Hospitals NHS Foundation Trust, UK

Joint Symposium 1

Sep. 26 (Thu), 14:30-16:00 		Room A
(2F)
Chair(s) Je-Jung Lee (Chonnam National University Medical School)
Stanley Riddell (Fred Hutchinson Cancer Center)
  • Jordan Gauthier

    14:30-15:00

    Strategies to Mitigate CAR T-Cell-Associated Cytokine Release Syndrome and Neurologic Toxicity

    Jordan Gauthier

    Fred Hutchinson Cancer Center, USA

  • Peter Riedell

    15:00-15:30

    Real-World Outcomes with CAR T-Cell Therapy for Lymphoid Malignancies

    Peter Riedell

    University of Chicago, USA

  • Seok Jin Kim

    15:30-16:00

    Real-World Data of CAR-T in Refractory Lymphoma in Korea

    Seok Jin Kim

    Sungkyunkwan University School of Medicine, Korea

Scientific Session 1

Sep. 26 (Thu), 14:30-16:00 		Room B
(2F)
Chair(s) Sung-Soo Yoon (Seoul National University College of Medicine)
Myung Geun Shin (Chonnam National University Medical School)
  • Zachariah DeFilipp

    14:30-15:00

    Role of Tissue Niches in Acute GI-GVHD Revealed by Spatial Transcriptomics

    Zachariah DeFilipp

    Massachusetts General Hospital, USA

  • Paul G. Richardson

    15:00-15:30

    Endotheliopathies after Transplant and Immune Therapies in Hematologic Malignancy, with a Focus on the Evolving Role of Defibrotide, Including Its Potential in the Endotheliitis of COVID-19

    Paul G. Richardson

    Dana-Farber Cancer Institute, USA

  • Luca Vago

    15:30-16:00

    "Leukemia Immune Escape in Posttransplantation Relapses: From Biology to Personalized Medicine (And Back) "

    Luca Vago

    IRCCS San Raffaele Scientific Institute, Italy

Scientific Session 2

Sep. 26 (Thu), 14:30-16:00 		Room C
(1F)
Chair(s) Jong Ho Won (Soonchunhyang University College of Medicine)
Ho Joon Im (University of Ulsan College of Medicine)
  • Xiao-Jun Huang

    14:30-15:00

    The Optimization for T-Cell Replete Haploidentical Hematopoietic Stem Cell Transplantation

    Xiao-Jun Huang

    Peking University People's Hospital, China

  • Takanori Teshima

    15:00-15:30

    PBSCT Using Posttransplant Cyclophosphamide from HLA-Matched and 1-2 Allele Mismatched Donor

    Takanori Teshima

    Hokkaido University, Japan

  • Satoshi Takahashi

    15:30-16:00

    Strategies to Enhance Graft Performance in Cord Blood Transplantation

    Satoshi Takahashi

    The University of Tokyo, Japan

Education Session 1

Sep. 26 (Thu), 14:30-16:00 		Room D
(1F)
Chair(s) Ho-Jin Shin (Pusan National University School of Medicine)
Byung Sik Cho (The Catholic University of Korea)
  • Jamin Koo

    14:30-15:00

    Assisting Treatment Selection Based on Big Data and Machine Learning

    Jamin Koo

    Department of Chemical Engineering, Hongik University, Korea

  • Jeong-Moo Lee

    15:00-15:30

    Strategies for Integrating ChatGPT and Generative AI into Clinical Studies

    Jeong-Moo Lee

    Department of Surgery, Seoul National University College of Medicine, Korea

  • Hyery Kim

    15:30-16:00

    Machine Learning Applications in Hematopoietic Cell Transplantation

    Hyery Kim

    University of Ulsan College of Medicine, Korea

Nursing Session 1

Sep. 26 (Thu), 16:40-18:10 		Room D
(1F)
Chair(s) Minjin Choi (Samsung Medical Center)
  • Hong Ghi Lee

    16:40-17:10

    Chasing after Blood Cancer for Forty Years

    Hong Ghi Lee

    Konkuk University Medical Center, Korea

  • Eun Seok Choi

    17:10-17:40

    "A 27-Year Journey as a Transplant Nurse ""Empathy, Passion, and Resilience"""

    Eun Seok Choi

    Asan Medical Center, Korea

  • Yeon-Soo Seo

    17:40-18:10

    A New Life Yet to Come: Twists and Turns in My Life as a Life Scientist and Cancer Patient

    Yeon-Soo Seo

    Department of Biological Sciences, KAIST, Korea

Joint Symposium 2

Sep. 26 (Thu), 16:40-18:20 		Room A
(2F)
Chair(s) Seong Kyu Park (Soonchunhyang University College of Medicine)
Takanori Teshima (Hokkaido University)
  • Kazuto Ogura

    16:40-17:05

    Aging Landscape and Pre-Transplantation Considerations for Elderly Patients in Japan

    Kazuto Ogura

    Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan

  • Yuki Taya

    17:05-17:30

    Transplantation Strategies and Outcome of Elderly Patients with Acute Leukemia in Japan

    Yuki Taya

    Toranomon Hospital, Japan

  • Dae Hun Kwag

    17:30-17:55

    Geriatric Functional Assessments and Their Utility for Standard Intensive Chemotherapy and HSCT

    Dae Hun Kwag

    The Catholic University of Korea, Korea

  • Joon Ho Moon

    17:55-18:20

    Transplantation Strategies and Outcome of Elderly Patients with Acute Leukemia in Korea

    Joon Ho Moon

    Kyungpook National University School of Medicine, Korea

Scientific Session 3

Sep. 26 (Thu), 16:40-18:10 		Room B
(2F)
Chair(s) Hoon Kook (Chonnam National University Medical School)
Deok Hwan Yang (Chonnam National University Medical School)
  • Jeremy Abramson

    16:40-17:10

    Choosing a CAR for Relapsed/Refractory DLBCL: Which CAR, for Whom, and When

    Jeremy Abramson

    Massachusetts General Hospital, Harvard Medical School, USA

  • Neil Berinstein

    17:10-17:40

    Cellular Therapy for Primary and Secondary CNS Lymphoma: Transplantation? or CAR-T?

    Neil Berinstein

    Sunnybrook Health Sciences Centre, Canada

  • Hyoung Jin Kang

    17:40-18:10

    Optimization of CAR-T Therapy for Acute Lymphoblastic Leukemia

    Hyoung Jin Kang

    Seoul National University College of Medicine, Korea

Scientific Session 4

Sep. 26 (Thu), 16:40-18:10 		Room C
(1F)
Chair(s) Nack-Gyun Chung (The Catholic University of Korea)
Seongsoo Jang (University of Ulsan College of Medicine)
  • Lisa J. McReynolds

    16:40-17:10

    Interpretation of Germline Variants of IBMFS in Adult Patients with Hematologic Diseases

    Lisa J. McReynolds

    National Cancer Institute, USA

  • Shinichi Kako

    17:10-17:40

    Hematopoietic Stem Cell Transplantation and Immunosuppressive Therapy in Aplastic Anemia

    Shinichi Kako

    Jichi Medical University Saitama Medical Center, Japan

  • Boram Kim

    17:40-18:10

    Genetic Diagnosis of Inherited Bone Marrow Failure Syndromes in the Era of Next-generation Sequencing

    Boram Kim

    Sungkyunkwan University School of Medicine, Korea

Satellite Symposium 1

Sep. 27 (Fri), 08:30-09:00 		Room A
(2F)
Chair(s) Seok Lee (The Catholic University of Korea)
  • Makoto Onizuka

    08:30-09:00

    Ponatinib and Chemotherapy for Adult Patients with Newly Diagnosed Ph+ ALL Based from the PhALLCON Trial

    Makoto Onizuka

    Tokai University School of Medicine, Japan

Oral Presentation 5

 Room A
(2F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Soo-Mee Bang (Seoul National University College of Medicine)
Sung Hwa Bae (Daegu Catholic University School of Medicine)
Speaker(s) 09:00-09:10 The Prognostic Impact of Allogeneic Stem Cell Transplantation on Patients with Myelodysplastic Syndromes/Neoplasms Wan-Hsuan Lee (National Taiwan University Hospital)
09:10-09:20 Results of Allogeneic Stem Cell Transplantation in Advanced Myelofibrosis Jong Hyuk Lee (The Catholic University of Korea)
09:20-09:30 Pure Red Cell Aplasia in Acute Myeloid Leukemia Patients after ABO Mismatched HSCT So Yeon Park (The Catholic University of Korea)
09:30-09:40 Efficacy and Safety of Salvage Chemotherapy Regimens in Relapsed or Refractory Acute Myeloid Leukemia Hun Seok Choi (Yonsei University College of Medicine)
09:40-09:50 Real World Transplantation Outcomes of Myelofibrosis Treated with Pre-transplant Splenic Irradiation Yu-Sung Chang (National Taiwan University Hospital)
09:50-10:00 Venetoclax/Azacitidine Followed by Allogeneic Transplantation Is as Good as Intensive Chemotherapy Followed by Allogeneic Transplantation for Patients of AML at First Remission Su-Peng Yeh (China Medical University Hospital)

Oral Presentation 6

 Room B
(2F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Eun Sun Yoo (Ewha Womans University College of Medicine)
Jun Eun Park (Korea University College of Medicine)
Speaker(s) 09:00-09:10 Successful Outcomes of Haploidentical Family Donor Hematopoietic Cell Transplantation in Pediatric Severe Aplastic Anemia Suejung Jo (The Catholic University of Korea)
09:10-09:20 Outcome of Allogenic Hematopoietic Stem Cell Transplantation in Leukodystrophies: A Single-Center Experience over 15 Years Hyun Jin Park (Seoul National University College of Medicine)
09:20-09:30 Comparable Outcome of Myeloablative Total Body Irradiation Conditioning and Chemo-conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing First Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Korean Registry-Based Study Kyung Taek Hong (Seoul National University College of Medicine)
09:30-09:40 Feasibility of Tandem Conditioning-Based Myeloablative HSCT for Pediatric Patients with Relapsed/Refractory Myeloid Hematologic Malignancies Jae Won Yoo (The Catholic University of Korea)
09:40-09:50 Response-Adapted Consolidation Therapy Strategy for Patients with Metastatic High-risk Neuroblastoma: Results of the SMC NB-2014 Study Hee Won Cho (Sungkyunkwan University School of Medicine)
09:50-10:00 Introduction of Bone Marrow Transplantation in Children in Uzbekistan Khilola Rustamova (Scientific and Practical Center of Pediatric Oncology, Hematology and Immunology of Uzbekistan)

Oral Presentation 7

 Room C
(1F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Hye Lim Jung (Sungkyunkwan University School of Medicine)
Yong Park (Korea University College of Medicine)
Speaker(s) 09:00-09:10 Graft-versus-Host Disease Prophylaxis with Post-Transplant Cyclophosphamide Better Preserves Regulatory T Cell Bu-Yeon Heo (Chungnam National University College of Medicine)
09:10-09:20 The Expression of TIM3 on Marrow-Infiltrating T cells Is Increased in Patients with Blood Cancers Who Relapse Early after Hematopoietic Stem Cell Transplantation Thi Thuy Duong Pham (Chungnam National University College of Medicine)
09:20-09:30 Mesenchymal Stem Cell-Derived Exosomes for Enhanced Proliferation of CD34+ Cells Kunye Kwak (Korea University College of Medicine)
09:30-09:40 Phase II Trial of Imatinib Mesylate in Patients with Idiopathic Hypereosinophilic Syndrome Dong Hyun Kim (Seoul National University College of Medicine)
09:40-09:50 Low Dose Fludarabine Is an Effective Conditioning Treatment to Suppress Relapse Rate in PT-CY-Based Haploidentical Peripheral Blood Stem Cell Transplantation Jinhang Kim (The Catholic University of Korea)
09:50-10:00 Novel Mechanisms of Leukemogenesis: Genome Reorganization by TET Loss of Function Myunggon Ko (Ulsan National Institute of Science and Technology)

Oral Presentation 8

 Room D
(1F)
Date & Time Sep. 27 (Fri), 09:00-10:00
Chair(s) Seok-Goo Cho (The Catholic University of Korea)
Jeong A Kim (The Catholic University of Korea)
Speaker(s) 09:00-09:10 Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) against Multiple Myeloma Manh Cuong Vo (Chonnam National University Medical School)
09:10-09:20 CAR-T Therapy in Taiwan: Outcomes and Adverse Events from a National Registry Analysis Xavier Cheng-Hong Tsai (National Taiwan University Hospital)
09:20-09:30 Risk-Stratification for DLBCL Patients Receiving ASCT in the Era of New Targeted Drugs: A Real-World Study in China Wen-Xuan Huo (Peking University People's Hospital)
09:30-09:40 Single-cell RNA Analysis of Peripheral T Cells in Chronic Lymphocytic Leukemia Relapse after Chemotherapy or Allogeneic Transplantation Ho Cheol Jang (Chonnam National University Medical School)
09:40-09:50 Prognostic Factors and Treatment Outcome of Allo-SCT for Lymphoid Malignancy Hyungsoon Kim (Yonsei University College of Medicine)
09:50-10:00 Efficacy and Safety of Cytokine-Induced Killer Cells Infusion Combined with TRUXIMA as Post-Remission Therapy in Old Aged High-Risk Diffuse Large B Cell Lymphoma Patients Gi June Min (The Catholic University of Korea)

Plenary Session 3

Sep. 27 (Fri), 10:20-11:00 		Room A
(2F)
Chair(s) Hyeoung-Joon Kim (Chonnam National University Medical School)
  • Hee-Je Kim

    10:20-11:00

    New Horizons in the Treatment of Acute Myeloid Leukemia

    Hee-Je Kim

    The Catholic University of Korea, Korea

Presidential Symposium

Sep. 27 (Fri), 11:00-11:40 		Room A
(2F)
Chair(s) Je-Jung Lee (Chonnam National University Medical School)
  • Nicolaus Kröger

    11:00-11:40

    Future Perspectives of HSCT in the Cellular Immunotherapy Era

    Nicolaus Kröger

    University Medical Center Hamburg-Eppendorf, Germany

Luncheon Symposium 6

Sep. 27 (Fri), 11:50-12:30 		Room A
(2F)
Chair(s) Chul Won Jung (Sungkyunkwan University School of Medicine)
  • Vikas Gupta

    11:50-12:30

    How to Optimize Outcomes of Transplant in Myelofibrosis?

    Vikas Gupta

    Princess Margaret Cancer Centre, Canada

Luncheon Symposium 7

Sep. 27 (Fri), 11:50-12:30 		Room B
(2F)
Chair(s) Hee-Je Kim (The Catholic University of Korea)
  • Sung-Yeon Cho

    11:50-12:30

    Optimal Managing of IMD in the Haematology Unit: Role of Vfend®, Cresemba®

    Sung-Yeon Cho

    The Catholic University of Korea, Korea

Luncheon Symposium 8

Sep. 27 (Fri), 11:50-12:30 		Room C
(1F)
Chair(s) Je-Hwan Lee (University of Ulsan College of Medicine)
  • Bipin Savani

    11:50-12:30

    Management of GVHD in 2024- From Steroid-to-steroid Sparing Approach

    Bipin Savani

    Vanderbilt University Medical Center, USA

Luncheon Symposium 9

Sep. 27 (Fri), 11:50-12:30 		Room D-1
(1F)
Chair(s) Ho-Jin Shin (Pusan National University School of Medicine)
  • Hyewon Lee

    11:50-12:30

    CMV Prophylaxis with Letermovir in Allo HSCT - Extended Use in High Risk Patients

    Hyewon Lee

    National Cancer Center, Korea

Luncheon Symposium 10

Sep. 27 (Fri), 11:50-12:30 		Room D-2
(1F)
Chair(s) Jin Seok Kim (Yonsei University College of Medicine)
  • Jeff Szer

    11:50-12:30

    Remaining Unmet Needs in Current Treatment and a New Treatment Option in PNH

    Jeff Szer

    Royal Melbourne Hospital, Australia

Scientific Session 5

Sep. 27 (Fri), 12:40-14:10 		Room A
(2F)
Chair(s) Sang Kyun Sohn (Kyungpook National University School of Medicine)
Joon Seong Park (Ajou University School of Medicine)
  • Melody Smith

    12:40-13:10

    Evaluating the Regulatory Mechanisms for the Impact of the Intestinal Microbiome on Chimeric Antigen Receptor T Cells

    Melody Smith

    Stanford University, USA

  • Kentaro Fukushima

    13:10-13:40

    Prolonged Gut Microbial Alterations in Post-Transplant Survivors of Allogeneic Hematopoietic Stem Cell Transplantation

    Kentaro Fukushima

    Osaka University Graduate School of Medicine, Japan

  • Armin Rashidi

    13:40-14:10

    Fecal Microbiota Transplantation in the Prophylactic Setting after Allogeneic Hematopoietic Cell Transplantation

    Armin Rashidi

    Fred Hutch Cancer Center, USA

Scientific Session 6

Sep. 27 (Fri), 12:40-14:10 		Room B
(2F)
Chair(s) Hyeon Jin Park (National Cancer Center)
Duck Cho (Sungkyunkwan University School of Medicine)
  • Peter Lang

    12:40-13:10

    Haploidentical HCT for Neuroblastoma

    Peter Lang

    University Children’s Hospital Tuebingen, Germany

  • Ho Joon Im

    13:10-13:40

    Graft Engineering and Adoptive Cell Therapy

    Ho Joon Im

    University of Ulsan College of Medicine, Korea

  • Junsang Doh

    13:40-14:10

    Modulating NK Cell Synapses for the Improvement of NK Cell Therapy

    Junsang Doh

    Department of Materials Science and Engineering, Seoul National University, Korea

Education Session 2

Sep. 27 (Fri), 12:40-14:10 		Room C
(1F)
Chair(s) Chul Won Choi (Korea University Guro Hospital)
Sung-Yong Kim (Konkuk University School of Medicine)
  • Sung-Eun Lee

    12:40-13:10

    Considerations before HSCT for Patients with MF

    Sung-Eun Lee

    The Catholic University of Korea, Korea

  • Junshik Hong

    13:10-13:40

    Considerations about HSCT for Patients with MF (Donor, Conditioning Regimen, Engraftment, GVHD Prophylaxis)

    Junshik Hong

    Seoul National University College of Medicine, Korea

  • Kyoung Ha Kim

    13:40-14:10

    Is HSCT Still the Effective Treatment for CML?

    Kyoung Ha Kim

    Soonchunhyang University College of Medicine, Korea

Scientific Session 7

Sep. 27 (Fri), 12:40-14:10 		Room D
(1F)
Chair(s) Chang-Ki Min (The Catholic University of Korea)
Hyeon-Seok Eom (National Cancer Center)
  • Paul G. Richardson

    12:40-13:10

    Next-Generation Novel Therapies in Multiple Myeloma

    Paul G. Richardson

    Dana-Farber Cancer Institute, USA

  • John Wagner

    13:10-13:40

    CAR-19 Expressing Regulatory T Cells to Enhance GVHD-free, Relapse-free Survival in Patients with High Risk CD19+ Hematological Malignancy: Rationale and Developmental Pathway

    John Wagner

    University of Minnesota, USA

  • Changsong Qi

    13:40-14:10

    CAR-T Cell Therapy in Gastrointestinal Cancers

    Changsong Qi

    Peking University Cancer Hospital & Institute, China

Joint Symposium 3

Sep. 27 (Fri), 14:20-16:00 		Room A
(2F)
Chair(s) Seong Kyu Park (Soonchunhyang University College of Medicine)
Anna Sureda (Catalan Institute of Oncology)
  • Annalisa Ruggeri

    14:20-14:45

    Current Status of Alternative Donor Transplantation Compared to Conventional Donor: EBMT Perspectives

    Annalisa Ruggeri

    IRCCS San Raffaele Hospital, Italy

  • Avichai Shimoni

    14:45-15:10

    KIR-Mismatch and Transplantation Outcome in Myeloid vs. Lymphoid Disease

    Avichai Shimoni

    Chaim Sheba Medical Center, Israel

  • Seo-Yeon Ahn

    15:10-15:35

    Outcome of Alternative Donor Transplantation in AML and MDS in Korea

    Seo-Yeon Ahn

    Chonnam National University Medical School, Korea

  • Jae Ho Yoon

    15:35-16:00

    Alternative Donor Hematopoietic Cell Transplantation (HCT): Korean Experiences and Optimization of Cord Blood and Haploidentical Donor HCT in Adult ALL

    Jae Ho Yoon

    The Catholic University of Korea, Korea

Debate Session 1

Sep. 27 (Fri), 14:20-15:10 		Room B
(2F)
Chair(s) Jin Seok Kim (Yonsei University College of Medicine)
  • Ji Hyun Lee

    14:20-14:35

    No Upfront ASCT

    Ji Hyun Lee

    Dong-A University College of Medicine, Korea

  • Myung-won Lee

    14:35-14:50

    Upfront ASCT

    Myung-won Lee

    Chungnam National University College of Medicine, Korea

  • 　

    14:50-15:10

    Debate

    　

    　, 　

Education Session 3

Sep. 27 (Fri), 14:20-15:50 		Room C
(1F)
Chair(s) Jae-Yong Kwak (Jeonbuk National University Medical School)
Hyoung Soo Choi (Seoul National University College of Medicine)
  • Yoshihiro Inamoto

    14:20-14:50

    Late Effect of Transplantation

    Yoshihiro Inamoto

    Fujita Health University School of Medicine, Japan

  • Hye Yoon Park

    14:50-15:20

    Post-HSCT Psychological Impact and Care

    Hye Yoon Park

    Department of Psychiatry, Seoul National University College of Medicine, Korea

  • Yoo Jin Lee

    15:20-15:50

    Fertility after Allogeneic Hematopoietic Stem Cell Transplantation

    Yoo Jin Lee

    University of Ulsan College of Medicine, Korea

Scientific Session 8

Sep. 27 (Fri), 14:20-16:05 		Room D
(1F)
Chair(s) Hong Ghi Lee (Konkuk University Medical Center)
Yeun Jun Chung (The Catholic University of Korea)
  • Stephanie Lee

    14:25-14:50

    Transplants from Unrelated Donors in the United States: Where We Are, Where We Are Going

    Stephanie Lee

    Fred Hutch Cancer Center, USA

  • Nicolaus Kröger

    14:50-15:15

    Transplants from Unrelated Donors in Europe: Where We Are and Where We Are Going

    Nicolaus Kröger

    University Medical Center Hamburg-Eppendorf, Germany

  • Shinichiro Okamoto

    15:15-15:40

    Designing the Future of Unrelated Donor Registries and Transplantation - JMDP Perspective -

    Shinichiro Okamoto

    Keio University School of Medicine, Japan

  • Keon Hee Yoo

    15:40-16:00

    Unrelated Donor Hematopoietic Stem Cell Transplantation in Korea

    Keon Hee Yoo

    Sungkyunkwan University School of Medicine, Korea

Debate Session 2

Sep. 27 (Fri), 15:10-16:00 		Room B
(2F)
Chair(s) Kyung-Nam Koh (University of Ulsan College of Medicine)
  • Hee Young Ju

    15:10-15:25

    Cons: Upfront HSCT Is Not Needed

    Hee Young Ju

    Sungkyunkwan University School of Medicine, Korea

  • Seung Min Hahn

    15:25-15:40

    Pro: Upfront HSCT Is Needed

    Seung Min Hahn

    Yonsei University College of Medicine, Korea

  • 　

    15:40-16:00

    Debate

    　

    　, 　

Joint Symposium 4

Sep. 27 (Fri), 16:30-18:10 		Room A
(2F)
Chair(s) Je-Jung Lee (Chonnam National University Medical School)
Chi-Cheng Li (Hualien Tzu Chi Hospital)
  • Sung-Hoon Jung

    16:30-16:55

    Current Role of ASCT in Multiple Myeloma

    Sung-Hoon Jung

    Chonnam National University Medical School, Korea

  • Nobuhiro Tsukada

    16:55-17:20

    Autologous Stem Cell Mobilization and Transplantation for Multiple Myeloma - Current Status and Future Perspectives in Japan -

    Nobuhiro Tsukada

    Japanese Red Cross Medical Center, Japan

  • Xiao-Dong Mo

    17:20-17:45

    Current Status of ASCT and the Role of CAR-T Cell Therapy in Managing Myeloma in China

    Xiao-Dong Mo

    Peking University People's Hospital, China

  • Jeffrey SY Huang

    17:45-18:10

    Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma in Taiwan

    Jeffrey SY Huang

    National Taiwan University Hospital, Taiwan

Scientific Session 9

Sep. 27 (Fri), 16:40-18:10 		Room B
(2F)
Chair(s) Yoo Hong Min (Yonsei University School of Medicine)
Kyoo-Hyung Lee (Ewha Womans University College of Medicine)
  • Gabriele Casirati

    16:40-17:10

    Base Editing of Surface Epitopes to Empower Cancer Immunotherapy and Beyond

    Gabriele Casirati

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA

  • Johannes Schetelig

    17:10-17:40

    Is AML Remission Induction Prior to alloHCT Necessary?

    Johannes Schetelig

    University Hospital Carl Gustav Carus Dresden, Germany

  • Dong-Yeop Shin

    17:40-18:10

    Salvage HSCT in AML: Strategies for Improvement

    Dong-Yeop Shin

    Seoul National University College of Medicine, Korea

Scientific Session 10

Sep. 27 (Fri), 16:40-18:10 		Room C
(1F)
Chair(s) Hyoung Jin Kang (Seoul National University College of Medicine)
So Ra Park (Regenerative Medicine Acceleration Foundation)
  • Daehyeon Baek

    16:40-17:10

    Regulatory Science Updates for Advanced Biological Products in Korea

    Daehyeon Baek

    Cell&Gene Therapy Products Division/MFDS, Korea

  • So Ra Park

    17:10-17:40

    Opportunities and Challenges on Clinical Translation of Cell & Gene Therapy in Korea

    So Ra Park

    Regenerative Medicine Acceleration Foundation, Korea

  • Michael Verneris

    17:40-18:10

    From Lab to Bedside: Navigating FDA Regulations for Novel Cell Therapies in the US

    Michael Verneris

    Children's Hospital Colorado, USA

Education Session 4

Sep. 27 (Fri), 16:40-18:10 		Room D
(1F)
Chair(s) Sung-Hyun Kim (Dong-A University College of Medicine)
Jung Woo Han (Yonsei University College of Medicine)
  • Seung-Ji Kang

    16:40-17:10

    Vaccination Guidelines after Hematopoietic Cell Transplantation

    Seung-Ji Kang

    Chonnam National University Medical School, Korea

  • Sung-Yeon Cho

    17:10-17:40

    Cytomegalovirus in Hematopoietic Cell Transplantation: Prophylaxis & Treatment

    Sung-Yeon Cho

    The Catholic University of Korea, Korea

  • Dong Won Baek

    17:40-18:10

    Appropriate Screening for cGVHD

    Dong Won Baek

    Kyungpook National University School of Medicine, Korea

Joint Symposium 5

Sep. 28 (Sat), 09:00-10:30 		Room A
(2F)
Chair(s) Seong Kyu Park (Soonchunhyang University College of Medicine)
Steve Oh (Independent Cell Therapy Leader)
  • Steve Oh

    09:00-09:30

    Supercharging the Delivery of Gene Therapies with Red Blood Cells

    Steve Oh

    Independent Cell Therapy Leader, Singapore

  • Joanne Mountford

    09:30-10:00

    Technical Issues and Hurdles of In Vitro Derived Blood Products

    Joanne Mountford

    Scottish National Blood Transfusion Service, UK

  • Eun Jung Baek

    10:00-10:30

    Manufacturing Blood Products Derived from Stem Cells

    Eun Jung Baek

    Department of Laboratory Medicine, Hanyang University College of Medicine; ArtBlood Inc., Korea

Scientific Session 11

Sep. 28 (Sat), 09:00-10:30 		Room B
(2F)
Chair(s) Deog-Yeon Jo (Chungnam National University College of Medicine)
Won-Sik Lee (Inje University College of Medicine)
  • Sejin Im

    09:00-09:30

    Defining a TCF1-Expressing Progenitor Allogeneic CD8+ T Cell Subset in Acute Graft-versus-Host Disease

    Sejin Im

    Department of Immunology, Sungkyunkwan University School of Medicine, Korea

  • Daniel Wolff

    09:30-10:00

    CSF-1R Inhibitor (Axatilimab) for Chronic GVHD

    Daniel Wolff

    University Hospital Regensburg, Germany

  • Tae Kon Kim

    10:00-10:30

    PD-1H/VISTA Expressed on Host Myeloid Cells Limits Acute Graft-versus-Host Disease

    Tae Kon Kim

    Vanderbilt University, USA

Scientific Session 12

Sep. 28 (Sat), 09:00-10:30 		Room C
(1F)
Chair(s) Seok Jin Kim (Sungkyunkwan University School of Medicine)
Byung-Su Kim (The Catholic University of Korea)
  • Stanley Riddell

    09:00-09:30

    Conquering Tumor Heterogeneity with Engineered T Cell Therapies

    Stanley Riddell

    Fred Hutchinson Cancer Center, USA

  • Anna Sureda

    09:30-10:00

    Changing the Treatment Landscape with CART Cells in Patients with B-Cell Lymphomas

    Anna Sureda

    Catalan Institute of Oncology, Spain

  • Hyungwoo Cho

    10:00-10:30

    Practical Challenges in Korea

    Hyungwoo Cho

    University of Ulsan College of Medicine, Korea

Joint Symposium 6

Sep. 28 (Sat), 10:40-11:40 		Room A
(2F)
Chair(s) Jae Ho Yoon (The Catholic University of Korea)
Elifcan Aladag Karakulak (Hacettepe University)
  • Elifcan Aladag Karakulak

    10:40-11:10

    Prevention and Treatment Strategy of Acute GVHD in Türkiye

    Elifcan Aladag Karakulak

    Hacettepe University, Türkiye

Scientific Session 13

Sep. 28 (Sat), 10:40-12:10 		Room B
(2F)
Chair(s) Keon Hee Yoo (Sungkyunkwan University School of Medicine)
Jae Wook Lee (The Catholic University of Korea)
  • Heather J. Symons

    10:40-11:10

    PTCy-Based Haploidentical HSCT in Pediatric Leukemia

    Heather J. Symons

    Johns Hopkins University School of Medicine, USA

  • Peter Bader

    11:10-11:40

    Optimizing Conditioning for Children and Adolescents with ALL

    Peter Bader

    Goethe University Frankfurt, Germany

  • Jae Wook Lee

    11:40-12:10

    PTCy-Based Haploidentical HSCT for Pediatric AML

    Jae Wook Lee

    The Catholic University of Korea, Korea

Nursing Session 2

Sep. 28 (Sat), 10:40-12:10 		Room C
(1F)
Chair(s) EunJung Joo (National Cancer Center)
  • Chin Kook Rhee

    10:40-11:25

    Management of Pulmonary Complication

    Chin Kook Rhee

    Department of Internal Medicine, The Catholic University of Korea, Korea

  • Kwan-Sik Seo

    11:25-12:10

    Health Rehabilitation Program for HSCT Patients

    Kwan-Sik Seo

    Department of Rehabilitation Medicine, Seoul National University College of Medicine, Korea